vincristine + dexamethasone + mercaptopurine + methotrexate + asparaginase + cyclophosphamide + cytarabine + teniposide + leucovorin

This is a multi-agent **chemotherapy combination** used primarily for the treatment of **acute lymphoblastic leukemia (ALL)**, particularly in pediatric and adult protocols based on regimens like Berlin-Frankfurt-Münster (BFM). It includes vincristine (microtubule inhibitor disrupting mitosis), dexamethasone (glucocorticoid inducing apoptosis in lymphoid cells), mercaptopurine (purine analog inhibiting DNA synthesis), methotrexate (folate antagonist blocking DNA replication), asparaginase (depleting asparagine to starve leukemic cells), cyclophosphamide (DNA alkylating agent), cytarabine (pyrimidine analog inhibiting DNA polymerase), teniposide (topoisomerase II inhibitor causing DNA breaks), and leucovorin (folate rescue to mitigate methotrexate toxicity). The regimen targets rapidly proliferating lymphoblasts through complementary mechanisms during induction, consolidation, and maintenance phases, achieving high cure rates in standard-risk ALL when administered intravenously, intrathecally, orally, or intramuscularly.